A multi-dose ophthalmic solution containing neomycin sulfate as the aminoglycoside component is manufactured as a sterile aqueous preparation with an osmolality of 280–320 mOsmol/kg and a finished pH of 5.0–7.5. The veterinary formulation falls under Regulation (EU) 2019/6 and 21 CFR 210/211 cGMP, with release testing under USP <771> for ophthalmic quality attributes, USP <71> for sterility, USP <51> for preservative effectiveness in multi-dose containers, and USP <789> for particulate matter. Neomycin sulfate is incorporated at 1.75 mg/mL of neomycin base equivalent in ophthalmic solution and at 3.5 mg/g in ophthalmic ointment; a narrow working range of 1.5–2.0 mg/mL is applied to solution batches because higher concentrations can increase the risk of corneal epithelial toxicity without a corresponding gain in aminoglycoside coverage. In production, the API is dissolved in water for injection at 20–25 °C, tonicity is adjusted with sodium chloride, and the solution is passed through a 0.22 μm PVDF sterilizing filter into LDPE or glass multi-dose dropper bottles under aseptic conditions; benzalkonium chloride at 0.01% w/v or another validated preservative is used unless single-dose units are specified. Terminal finished product types include 0.5 mL to 15 mL multi-dose dropper bottles, single-use ophthalmic vials, and sterile ophthalmic ointments in aluminum tubes. Process bottlenecks in ophthalmic filling lines typically arise from foaming during preservative mixing and from low-viscosity solution splashing in multi-head piston fillers; vacuum-assisted filling and low-foam vented agitators are used to maintain fill weight uniformity below ±1.5%.

For neonatal calf and weaned piglet enteric colibacillosis, neomycin sulfate is delivered as an oral tablet, capsule, or bolus in which the API is present at 250 mg or 500 mg neomycin sulfate per dosage unit, constituting 45–60% w/w of the core formulation. The finished product is controlled under 21 CFR 210/211 cGMP, with potency determined by USP <81> microbial assay and disintegration evaluated by USP <701>; the active substance itself must conform to the Ph. Eur. monograph for neomycin sulfate, including sulfate content and related substances limits. Direct compression is generally unsuitable because the micronized API exhibits poor flow and high hygroscopicity; instead, a dry granulation route with roller compaction at 40–80 bar roll pressure, milling to D50 of 200–400 µm, and final compression to core hardness of 90–150 N is used. The formulation contains 35–45% microcrystalline cellulose or lactose monohydrate, 3–5% crospovidone, 0.5–1.5% magnesium stearate, and a moisture barrier film coating based on HPMC or PVA. Batch-related failures on rotary tablet presses are most often caused by capping at low moisture content below 2.0% or picking when granulate moisture exceeds 4.5%; therefore the granulation is equilibrated to 2.5–3.5% residual moisture before compression. Finished product types include 125 mg, 250 mg, and 500 mg film-coated tablets, hard gelatin capsules, and large animal oral boluses with a film seal. Because neomycin sulfate can discolor in the presence of reducing sugars, lactose monohydrate is preferred over glucose and the blend is protected from open-air storage at relative humidity above 60%.

Why Does Neomycin Sulfate Soluble Powder Require Hard-Water Sequestering in Poultry Lines?

In poultry and swine drinking-water medication, neomycin sulfate is delivered as a dry, freely flowing water-soluble powder containing 325 mg/g neomycin sulfate, with anhydrous glucose or lactose as the carrier and citric acid or sodium citrate as the pH and hard-water control agent. Under USP <81>, the reconstituted solution must retain no less than 90% of labeled potency for 24 h at 25 °C, and the powder must dissolve to a clear or slightly hazy solution in 5–10 min when added to water at 20 °C. The inclusion rate in medicated water is calculated to provide 11–22 mg/kg body weight per day for 3–5 days; in practice, a 1:128 proportioner draws a stock solution of 0.25–0.50 mg/mL neomycin sulfate into drinking lines, although the exact stock concentration is adjusted by the prescribing veterinarian based on water intake and biomass. During dry blending in a ploughshare or ribbon mixer, the API is pre-milled to D90 < 150 µm and the finished powder is filled into low-moisture barrier sachets or bulk drums with residual moisture below 5.0%. Hard-water sequestering is necessary because calcium and magnesium carbonate concentrations above 200 ppm can reduce the rate of dissolution and compromise uniform delivery through nipple drinkers; citric acid at 2–5% w/w is used to maintain the reconstituted pH between 5.0–7.5 and to chelate divalent cations in the proportioner. Terminal finished product types include 50 g to 1 kg water-soluble powder sachets, bulk packs for poultry integration, and effervescent granules for on-farm stock tank use. The powder must not be combined with alkaline chlorination concentrates or strong oxidizing disinfectants in the same stock solution because aminoglycoside potency is lost at pH above 8.0.

When Neomycin Sulfate Is Dispersed in a Mineral Carrier at 70–140 g/t

Feed-grade neomycin sulfate is incorporated into complete feed for swine, poultry, cattle, sheep, and goats under 21 CFR 558.128, which defines the approved inclusion range of 70–140 g neomycin sulfate per short ton (907 kg) of complete feed, equivalent to 77–154 mg/kg. The Type A medicated article is first diluted through a Type B premix with calcium carbonate, rice hulls, or ground corn mineral carrier; batch documentation must include the serial dilution factor and the coefficient of variation of the active substance, which is maintained below 5% in ribbon or paddle mixers operating at 10–20 rpm. Production experience on feed-mill lines shows that a single-step addition of Type A directly into a final mixer produces unsatisfactory assay uniformity when the particle size of the carrier exceeds 600 µm; therefore a three-step geometric dilution sequence is imposed. Because neomycin sulfate is hygroscopic, the premix is bagged in multi-wall paper or polyethylene-lined sacks and stored at relative humidity below 60%. The same feed-grade specification limits the consecutive feeding duration and the pre-slaughter withdrawal period, which is species-specific and printed in the approved labeling under 21 CFR 558.128; no terminal feed dilution may legally extend the withdrawal period. Terminal finished product types include medicated complete feed, Type C feed, pelleted concentrate with neomycin applied after pelleting to avoid thermal loss above 85 °C, and top-dress mineral packs. The main incompatibility is with bentonite-based pellet binders and high-iron mineral premixes, which can bind the aminoglycoside and depress assay recovery below 95%.

Parenteral Neomycin Sulfate and the Renal Safety Ceiling in Polyionic Diluents

Because the aminoglycoside has a narrow therapeutic index and accumulates in renal proximal tubular cells after parenteral administration, injectable neomycin sulfate preparations occupy a restricted position in veterinary therapeutics; ototoxicity and neuromuscular blockade are additional risks when the finished injection is administered concurrently with neuromuscular blocking agents or general anesthetics. A compounded parenteral formulation, where regional law permits, is typically prepared as a sterile solution at 10–50 mg/mL neomycin sulfate in 0.9% sodium chloride or 5% dextrose; concentrations above 50 mg/mL are not recommended because the resulting osmolality can exceed 600 mOsmol/kg and requires slow infusion rather than bolus intramuscular injection. Release specifications include USP <1> for injections, USP <71> for sterility, USP <85> for bacterial endotoxins below the limit calculated from the maximum dose, and USP <788> for particulate matter. Aseptic filtration through 0.22 μm PVDF or PES membrane is used; the final solution is filled into amber Type I glass vials under nitrogen if oxidative degradation is observed. Published data for the specific configuration of a terminally sterilized multi-dose neomycin injection is limited, and many pharmacopoeias do not define a dedicated neomycin sulfate injection monograph, so the manufacturer must establish process-specific stability data rather than relying on compendial default storage. Terminal finished product types include single-dose vials, intramuscular injection solutions, and intravenous admixtures for hospital use. Neomycin injection is contraindicated in food-producing animals in some jurisdictions because residue depletion data may be incomplete; use in animals with elevated creatinine or dehydration is an operational boundary that must be stated on the compounding record.

Assessing Teat-End Retention Without Xanthan Gum in Intramammary Infusions

For mastitis therapy in lactating or dry dairy cattle, intramammary infusion products containing neomycin sulfate are packaged as single-dose plastic syringes designed to remain in the udder quarter after infusion and to be stripped out within the labeled milk-withholding interval. The single-dose syringe contains 500 mg neomycin sulfate per 10 mL, equivalent to 50 mg/mL; in combination products, polymyxin B sulfate and prednisolone acetate are included at concentrations fixed by the approved marketing authorization. The formulation is controlled for sterility by USP <71>, for bacterial endotoxins by USP <85>, and for extractables from the plastic syringe by USP <661.1>. During compounding, the aqueous phase containing the API is mixed with a thixotropic vehicle, often a combination of glyceryl monostearate and light liquid paraffin, at 1,000–5,000 cP apparent viscosity at 20 °C; suspended neomycin sulfate particle size is reduced to D90 < 25 µm by high-shear homogenization to prevent syringe tip clogging and to ensure even udder distribution. Xanthan gum is frequently avoided because its ionic nature and variable hydration in mastitic milk may produce uneven gel fragmentation and rapid teat-end leakage; instead, a non-ionic thixotropic agent is selected. Terminal finished product types include lactating-cow intramammary syringes, dry-cow intramammary syringes with prolonged base retention, and combination tubes containing neomycin sulfate with penicillin or polymyxin B. The primary process bottleneck is maintaining sterility during molten vehicle cooling below 45 °C before aseptic addition of the temperature-sensitive aminoglycoside suspension.